Please assess the completion status of the following clinical trial:

Trial Title: Fresolimumab In Systemic Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet ACR criteria for diffuse systemic sclerosis~* \< 24 months since onset of first SSc manifestation other than Raynaud's phenomenon~* Modified Rodnan Skin Score ≥ 15~* Male or female adult ( ≥ 18 years of age)~* Able and willing to give written informed consent and comply with study protocol~Exclusion Criteria:~* Moderate or severe pulmonary disease w/ FVC \< 80% or DLCO \< 70% or ground glass and fibrosis \> 20% of lung fields by HRCT~* Treatment with investigational drug within 4 weeks of screening~* Ongoing use of high dose steroids (\> 10mg/day) or unstable steroid dose in past 4 weeks~* Treatment with immunosuppressive, cytotoxic, or antifibrotic drug within 4 weeks of screening~* Positive for HIV, HBV, and/or HCV~* Known active infection (bacterial, viral, fungal, mycobacterial, or other); not including fungal infection of nail beds or any major infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening~* Patients w/ history of malignancy or premalignant lesion~* History of keratoacanthoma or squamous cell carcinoma~* Moderate to severe hepatic impairment~* SSc renal crisis within 6 months or creatinine \> 2.0~* Lack of IV access for medication administration~* Moderate or severe cardiac disease with significant arrhythmia, heart failure, or unstable angina~* Anemia (Hb \< 8.5 gm/dL)~* Thrombocytopenia or blood clotting disorder~* Patients with organ transplant (including allogeneic bone marrow transplant)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fresolimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).